DTP3
DTP3 TFA is a potent and selective GADD45β/MKK7 inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway[1].
Product Specifications
CAS Number
1809784-29-9
UNSPSC
12352209
Hazard Statement
H302, H315, H319, H335
Target
DNA/RNA Synthesis; JAK
Type
Peptides
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/dtp3.html
Purity
98.45
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL
Smiles
O=C(N[C@H](CC1=CC=CC=C1)C(N)=O)[C@H](NC([C@H](NC(C)=O)CC2=CC=C(O)C=C2)=O)CCCNC(N)=N
Molecular Formula
C26H35N7O5
Molecular Weight
525.60
Precautions
H302, H315, H319, H335
References & Citations
[1]Tornatore L, et al. Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7inhibitor and clinical candidate, DTP3. Toxicol Rep. 2019 Apr 19;6:369-379.|[2]Tornatore L, et al. Cancer-selective targeting of the NF-κB survival pathway with GADD45β/MKK7 inhibitors. Cancer Cell. 2014 Oct 13;26 (4) :495-508.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CG50-1mg 1 mg
Recombinant Mouse Tumor Necrosis Factor Receptor I/TNFRSF1A/CD120a
Sign In for Pricing
View Details 490771 100 µL
RORC (Nuclear Receptor ROR-gamma, RAR-related Orphan Receptor C)
Sign In for Pricing
View Details 